logo
Plus   Neg
Share
Email
Comment

MyoKardia Gets Orphan Drug Designation For MYK-461 For Treatment Of OHCM

MyoKardia, Inc. (MYOK), a clinical stage biopharmaceutical company for the treatment of heritable cardiovascular diseases, announced Monday that the U.S. Food and Drug Administration has granted the company Orphan Drug Designation for MYK-461 for treatment of symptomatic obstructive hypertrophic cardiomyopathy or oHCM, a subset of hypertrophic cardiomyopathy or HCM.

MYK-461, an orally administered small molecule, is the Company's lead product candidate and the first therapy designed to target the underlying cause of HCM. MyoKardia's proposed initial indication for MYK-461 is oHCM.

Three Phase 1 clinical trials have been initiated to assess MYK-461's ability to modulate cardiac myosin by measuring reduction in cardiac muscle contractility via echocardiography.

The FDA Office of Orphan Products Development grants orphan status to support development of medicines for underserved patient populations, or rare disorders that affect fewer than 200,000 people in the United States.

The company noted that orphan drug designation provides it with certain benefits, including market exclusivity upon regulatory approval if received, exemption of FDA application fees and tax credits for qualified clinical trials.

There are currently no approved therapeutic products indicated for the treatment of HCM. Patients are typically prescribed one or more drugs indicated for the treatment of hypertension, heart failure or other cardiovascular disorders more generally.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
BlackRock Inc., the world's largest asset manager, said it plans to speak with gun makers and distributors following public outcry after the Florida high school shooting that killed 17 people. BlackRock, which had $6.3 trillion in assets under management as of December 31, 2017, holds shares in gun makers Sturm Ruger & Co. Inc. as well as American Outdoor Brands Corp. An upgraded boarding in Southwest Airline will cost you more. The airline usually not assign seats to passengers, but one can choose from an open seat. The Upgraded Boarding will allow passengers to choose from A1 - A15 boarding positions. The cost for these positions would be $30, $40 and $50, depending on flight and route. This option can be availed from the ticket counter or gate. Citigroup Inc.'s co-head of mergers and acquisitions, Peter Tague, is leaving the company, according to media reports, citing people familiar with the matter. Tague has been co-head of Global M&A business at Citigroup since March 2012, alongside Cary Kochman and Mark Shafir. It was not immediately clear what Tague intends to do after he leaves Citigroup.
comments powered by Disqus
Follow RTT